Ocugen, Inc. (OCGN) |
|
0.9201 -0.033 (-3.44%)
|
03-22 15:49 |
|
Open: |
0.9691 |
Pre. Close: |
0.9529 |
|
High:
|
0.9691 |
Low:
|
0.8917 |
|
Volume:
|
7,054,871 |
Market Cap:
|
208(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 3:20:15 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 1.17 One year: 1.28 |
| Support: |
Support1: 0.84 Support2: 0.7 |
| Resistance: |
Resistance1: 1 Resistance2: 1.1 |
| Pivot: |
0.95 |
| Moving Average: |
MA(5): 0.95 MA(20): 0.95
MA(100): 1.29 MA(250): 1.94 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1  |
| Stochastic oscillator: |
%K(14,3): 44.9 %D(3): 54 |
| RSI: |
RSI(14): 40 |
| 52-week: |
High: 3.72 Low: 0.84 |
| Average Vol(K): |
3-Month: 6,861 (K) 10-Days: 10,728 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OCGN ] has closed above bottom band by 24.4%. Bollinger Bands are 44.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.96 - 0.97 |
0.97 - 0.97 |
|
Low:
|
0.92 - 0.93 |
0.93 - 0.93 |
|
Close:
|
0.94 - 0.95 |
0.95 - 0.96 |
|
Company Description |
|
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania. |
Headline News |
Tue, 21 Mar 2023
How does Ocugen Inc. (OCGN) change from a tortoise to a hare? - SETE News
Tue, 21 Mar 2023
Ocugen Inc. (OCGN) Stock: A Closer Look at the Analyst Ratings - The News Heater
Thu, 16 Mar 2023
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Tue, 07 Mar 2023
Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference - Yahoo Finance
Mon, 06 Mar 2023
Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief ... - Ocugen
Wed, 01 Mar 2023
Chardan Capital Upgrades Ocugen (OCGN) - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
219 (M) |
| Shares Float |
215 (M) |
|
% Held by Insiders
|
2.4 (%) |
|
% Held by Institutions
|
38.6 (%) |
|
Shares Short
|
44,970 (K) |
|
Shares Short P.Month
|
40,650 (K) |
Stock Financials |
|
EPS
|
-0.26 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.54 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-40.5 |
|
Return on Equity (ttm)
|
-73.2 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.17 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.35 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-56 (M) |
|
Levered Free Cash Flow
|
-30 (M) |
Stock Valuations |
|
PE Ratio
|
-3.61 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.68 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-3.57 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-09-29 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
